By

Gisela Pairo
On occasion of World TB Day, we talk to EU-PEARL specialists on Tuberculosis (TB) Daniella Maria Cirillo and Riccardo Alagna to learn about where we are in the fight against TB, what is needed to meet UN targets for 2030 and how this IMI project is contributing to it.   Today is World TB day....
Read More
The COVID-19 pandemic has created renewed appreciation for the tremendous impact healthcare and pharmaceutical innovation has on the health and daily lives of society. Public-private partnerships to develop vaccines and therapeutics in response to the pandemic have significantly raised public awareness about clinical trials and global clinical trial infrastructure. Established clinical development paradigms in which...
Read More
Martin Posch, Professor at the Medical University of Vienna, and member of EU-PEARL will introduce the project at this year’s DIA/FDA Biostatistics Industry and Regulator Forum, which is held from April 14-16 in a virtual format. This is an open forum for the discussion of statistical issues in the development of medical products, bringing together...
Read More
Non-alcoholic fatty liver disease (NAFLD) is defined as the buildup of fat in the liver. Its more advanced form, non-alcoholic steatohepatitis (NASH), is characterized by inflammation and damage to liver cells, which can lead to tissue scarring or fibrosis. These are silent diseases where patients initially have few or no symptoms, hampering early detection. However,...
Read More
By Tom Parke, Berry Consultants The principal idea of a platform trial is as simple as it is radical. Whereas a conventional clinical trial tests a potential new treatment for a disease, ending it once we have enough data to conclude whether the treatment is effective or not, a platform trial tests more than one...
Read More
NASH-TAG is a yearly conference devoted to bringing together NASH experts for an invaluable educational experience. This event is a two-day conference where clinicians and researchers from industry and academia share the most relevant changes in the field regarding therapy and diagnosis of NASH. 2021 edition will focus on the latest clinical trial results, factors...
Read More
EU-PEARL member and Professor at the Medical University of Vienna, Martin Posch, will offer an overview of this IMI project during the 67th Biometric Colloquium “Scenes from Biostatistics” organized by the Institute of Biostatistics and Clinical Research of the Westfälische Wilhelms-Universität Münster. The Conference will take place online from March 14-17, 2021. Posch will deliver the lecture Statistical Issues...
Read More
In this interview, Elias Laurin Meyer, biostatician, PhD student at the Medical University of Vienna (MUW) and early career researcher in EU-PEARL, tells us about his experience and the contribution he is making to the project. What is your area of expertise? I studied Statistics and I am currently doing a PhD in Biostatistics. Starting...
Read More
EU-PEARL is set to transform the way clinical trials are conducted by developing tools and methodologies to create Integrated Research Platforms (IRPs). This novel approach has the potential to make drug development processes more efficient and faster. A pivotal element is the master protocol, which is still a relatively novel concept. Its implications in critical...
Read More
At the recent stakeholder workshop, it was clear that EU-PEARL is focussed on ensuring the clinical trials of the future are going to be fit for purpose for all stakeholders to draw robust conclusions from them. This is an exciting time to be involved in clinical trial design; understanding what the benefits and risks of...
Read More
1 3 4 5 6 7 8

Sign up to stay informed


    We will process your data to deliver our quarterly updates to your inbox. You can view our Privacy Policy here or contact us at info@eu-pearl.eu